The article explains that in the United States, which medical treatments become widely used depends largely on the healthcare system’s regulatory approval, coding, and insurance reimbursement structure, not only clinical effectiveness. Therapies that fit standardized billing and predictable cost models scale faster, while many regenerative medicine treatments remain limited because they introduce uncertainty in long-term utilization and actuarial forecasting. The authors argue this is a structural feature of the system rather than corruption, and that regenerative medicine must succeed by integrating with existing frameworks—following FDA regulations, producing strong safety and outcome data, standardizing protocols, and demonstrating long-term cost benefits—so it can eventually fit within reimbursement systems and expand access.
How Reimbursement Architecture Shapes What Scales in American Medicine — and Why Regenerative Innovation Must Integrate, Not Bypass, the System
By Martin Johns MD, Gregory Laurence MD and Stanford Silverman
Start With the Structural Question
If a therapy restores tissue integrity, reduces inflammation, and improves functional mobility — why does it often sit outside traditional insurance reimbursement pathways?
Why do certain interventions scale rapidly while others remain niche, self-pay, or administratively constrained?
The answer is neither conspiracy nor corruption.
It is architecture.
American healthcare is not merely a clinical enterprise.
It is an actuarial and reimbursement system layered atop clinical practice.
What scales must fit coding systems, actuarial predictability, regulatory guidance, and reimbursement frameworks.¹
That reality is not villainy.
It is infrastructure.
Episode I — Reimbursement as Structural Filter
Every therapy in the United States passes through three gates:
If a therapy cannot be coded, it cannot be billed.
If it cannot be billed, it cannot be widely adopted.
If it cannot be widely adopted, it remains peripheral.
Administrative systems prioritize:
Healthcare policy analysis documents how reimbursement protocols and administrative frameworks significantly shape what therapies survive at scale.¹
Innovations requiring individualized protocols or emerging biologic frameworks encounter friction — not necessarily because of safety failure, but because of actuarial uncertainty.
Episode II — The Stability Imperative
Hospitals forecast volume.
Insurers forecast utilization.
Pharmaceutical firms forecast duration.
Regulators forecast risk exposure.
Modern healthcare depends on predictability.
Regenerative medicine introduces a different economic dynamic:
These dynamics introduce uncertainty into actuarial modeling.
As described in the FPC healthcare white paper, corporate incentives and reimbursement architecture reward continuity and predictable utilization patterns.²
The friction is structural.
Episode III — Regulatory Reality and Compliance
It must be stated clearly:
All regenerative therapies practiced within the United States must comply with FDA guidance and federal regulatory frameworks.
Expanded umbilical cord stem cell use has faced regulatory restriction within the United States, contributing to the movement of some expanded-cell practices outside U.S. jurisdiction.³
Responsible domestic practice requires:
As discussed in the Becker’s podcast transcript, safety screening, laboratory control, viability testing, and documentation standards are central to responsible regenerative practice.³
Innovation must integrate with oversight — not bypass it.
Episode IV — Administrative Friction
The FPC white paper documents the administrative intensity shaping physician practice environments, including coding constraints, authorization requirements, and compliance burdens.⁴
These structures influence bandwidth and adoption decisions.
Innovation that requires non-standardized documentation faces processing difficulty within systems designed for repeatable, coded interventions.
Administrative friction is not necessarily ideological.
It is procedural.
Episode V — From Managed Disease to Agency Restoration
Chronic disease management has become normalized:
These models provide predictability.
Regenerative approaches aim to restore functional capacity.
This is not a promise of cure.
It is a pursuit of restored biological agency.
The FPC white paper frames reform around restoring patient-centered priorities and healthcare’s foundational healing mandate.⁵
Agency restoration aligns with that mandate.
Episode VI — The Agency Dividend Model
When biological function improves, it generates downstream economic effects:
This produces what may be described as an Agency Dividend.
Rather than asking whether regenerative models disrupt revenue, policymakers may more productively evaluate long-term cost-offset and functional restoration metrics.
The economic conversation must expand beyond immediate billing codes toward longitudinal system impact.¹ ²
Episode VII — Regulatory Assimilation
The path forward for regenerative medicine is not confrontation.
It is regulatory assimilation.
That includes:
As discussed in the Becker’s transcript, transparency, viability testing, and standardized laboratory processes are central to credible regenerative practice.³
Institutions evolve when innovation becomes legible within regulatory language.
Episode VIII — Physician Realities
Physicians operate inside reimbursement systems.
The FPC white paper documents how financial and administrative protocols influence clinical environments.⁴
Innovation must respect that structure.
Regenerative medicine’s maturation depends on:
Professional evolution requires operational rigor.
Episode IX — America’s Opportunity
The United States leads in biomedical discovery.
The opportunity is not whether regenerative medicine exists.
It is whether reimbursement and regulatory systems can modernize to incorporate:
Reform requires integration.
Not destabilization.
Final Reckoning — Evolution Without Recklessness
Big Pharma is not a villain.
Insurers are not adversaries.
Regulators are not enemies.
They are systems built for stability.
Regenerative medicine introduces new variables.
The responsible path forward is disciplined integration supported by:
Healthcare does not resist healing.
It resists uncertainty.
Reduce the uncertainty.
Demonstrate the dividend. Integration becomes possible.
Footnotes
Disclaimer: This article discusses certain companies and their products or services as potential solutions. These mentions are for illustrative purposes only and should not be interpreted as endorsements or investment recommendations. All investment strategies carry inherent risks, and it is imperative that readers conduct their own independent research and seek advice from qualified investment professionals tailored to their specific financial circumstances before making any investment decisions.
The content provided here does not constitute personalized investment advice. Decisions to invest or engage with any securities or financial products mentioned in this article should only be made after consulting with a qualified financial advisor, considering your investment objectives and risk tolerance. The author assumes no responsibility for any financial losses or other consequences resulting directly or indirectly from the use of the content of this article.
As with any financial decision, thorough investigation and caution are advised before making investment decisions.
How Modern Disinfection Became a Ritual of Harm—and How Science Is Beginning to Whisper the Truth By Martin Johns MD and Stanford Silverman I. The...
Martin C. Johns MD
Reclaiming the American Economic Covenant – and the Financial Policy Council’s Mandate for Policy Accountability By Paul Mourino (Board Member, Financial Policy Council) Introduction: Davos,...
Paul Mourino
Two islands, one equation: constrained inputs, constrained outputs Islands operate like closed-loop organisms. In medicine, when an organ’s clearance system fails—when the lymphatics don’t drain,...
Stanford Silverman
We Extend Our Gratitude to Our Partners
